Advertisement
"The progression into Phase II clinical trials with Alnylam's therapeuticis significant as it is the first RNAi program in clinical trials usinginhalation. We are seeing a number of companies turn to advanced nebulizationwith our eFlow platform, because the flexibility allows the development of newrespiratory therapies that are delivered to the lungs in a faster, moreeffective manner," said Geoff A. Hunziker, President of eFlow LLC.
Advertisement
Respiratory syncytial virus (RSV) is a highly contagious virus that causesinfections in the upper and lower respiratory tract associated withpredictable seasonal outbreaks worldwide. RSV infection is the most commoncause for infant hospitalization (more than 100,000 hospitalizations annuallyin the U.S.), and the virus is a significant pathogen in the elderly. The RNAitherapeutic agent ALN-RSV01 is a small interfering ribonucleic acid (siRNA)targeting the messenger RNA of the RSV N gene to prevent viral replication. Todeliver ALN-RSV01 to the site of infection, the RNA therapeutic is beingadministered as an aerosol in a highly efficient pulmonary delivery system, anoptimized eFlow platform nebulizer, with high drug output, optimized dropletsize, and low residual drug loss.
For more information on the Phase II study, visit http://www.alnylam.com.
About eFlow
eFlow, an electronic, portable nebulizer platform, enables extremelyefficient aerosolization of liquid medications via a vibrating, perforatedmembrane. Compared to other nebulizer systems, eFlow can produce aerosols witha very high density of active drug, a precisely defined droplet size, and ahigh proportion of respirable droplets delivered in the shortest possibleamount of time. Combined with its silent mode of operation, small size (itfits in the palm of your hand), light weight, and battery use, eFlow helpsreduce the burden of taking daily inhaled treatments.
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies. Basedon PARI's 100-year history working with aerosols, PARI Pharma specializes intreatments for pulmonary and nasal administration optimized to advanceddelivery platforms, such as eFlow.
Focusing on comprehensive inhalation therapy development, includingoptimized nebulizer formulations, analytics, and aerosol characterization,PARI Pharma has several clinical development programs ongoing, eitherpartnered or proprietary. PARI Pharma, a PARI Medical Holding company, islocated in Munich, Germany, with a major presence in the United States. Onlineat http://www.paripharma.com
Additional information is available by contacting Kirsten Ayars at 805-452-7909 or Geoff Hunziker at 831-372-3580.
SOURCE PARI Pharma
